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AUDIT REPORT 
 
UK National Audit of Early Syphilis Management. Case Notes Audit: 
Contact Tracing, Information giving, Follow-up and Outcomes 
 
Hugo McClean FRCPI, David Daniels FRCP, Chris Carne MD FRCP, Paul Bunting MSc,  
Rob Miller FRCP 
 
on behalf of the National Audit Group of the British Association for Sexual Health and HIV 
 
Summary: Contact tracing was provided for 683/781 (87%, regional range 57-97%) cases, and 
identified 997 traceable contacts of whom 511 (51%) were seen, short of the recommended 
standard of 60%. However, the performance range for this standard was 26-70%, with 7 Regions 
achieving 60% or more. Two hundred and fifteen of 511 (42%, range 3-73%) contacts had 
syphilis. Treatment completion was recorded for 691 (88%, range 71-100%) cases, and resolution 
of lesions for 348/469 (74%, range 40-96%) cases. Nationally, 419/764 (55%, range 37-70%) 
cases were recorded as having a two dilution (fourfold) or greater decrease in non-treponemal test 
titre within 3-6 months after treatment; not achieving this titre decrease was mainly attributable to 
non-attendance for follow-up and failure of titre levels to fall. Follow-up of infectious syphilis in UK 
genitourinary medicine clinics is poor and falls far short of that recommended by National 
Guidelines. Only 16 (2%) cases had follow-up at intervals approximating to 1, 2, 3, 6 & 12 months, 
and only 312 (40%, range 5-61%) cases attended at least two follow-up visits. Only 17 (7%) of all 
236 oral treatments (including switches to oral treatment), and 33 (27%) of 123 cases with HIV 
infection were recorded as designated annual follow-up. Further work is needed to determine 
factors that account for the wide variation between Regions in contact tracing and follow-up 
performance.   
 
Keywords (MeSH): Syphilis, Medical Audit, Nursing Audit, Contact Tracing, Patient Education, 
Outcome Assessment (Health Care) 
 
Introduction 
This paper accompanies the report on the case note audit of diagnosis and treatment of early 
syphilis carried out in 2004 by the National Audit Group in response to increasing numbers of 
cases of infectious syphilis in the UK.1 
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Methods 
The Audit methodology and organisation is described in the report on diagnosis and treatment.1 
This part of the Audit provides data that allows comparisons of practice in contact tracing, 
information giving, follow-up and outcomes to be made between Regions, as well as to national 
averages and National Guidelines.2 Data aggregated by NHS Trusts within Regions, not published 
in this paper, has been provided to Chairs of Regional Audit Groups to allow service comparisons 
between Trusts.  
 
 
Results 
Contact tracing  
The case note audit asked two questions about contact tracing: “Was contact tracing carried out” 
and “If yes, with whom … .” Therefore, two measures of contact tracing could be calculated: the 
total number of cases provided with contact tracing, and the number having contact tracing 
provided by each healthcare profession. Table 1 shows performance based on both questions. Of 
673 cases who were provided with contact tracing by any healthcare professional, 611(91%) had 
contact tracing provided by health advisers. It is noteworthy that there is strong agreement 
between the rates of contact tracing provision obtained in both these questions.  Contact tracing 
identified 997 traceable contacts, and the national ratio of traceable contacts to number of index 
cases was 1.28 (regional range 0.43 to 1.79). Table 1 shows the wide range of positive adult 
contact rates reported, although 8 of the 16 Regions had positive adult contact rates above 46% 
(see discussion).  
 
Information giving 
The following are the performances with regard to provision of the information items specified in 
the National Guidelines:2 partner notification: 657 (84%, range 61-97); it is noteworthy that this 
figure agrees with the other two measures of contact tracing described above; health education: 
545 (70%, range 46-100); and past treatment: 373 (48%, range 9-78%). Only 45 (6%, range 0-
13%) patients were provided with a letter documenting treatment. 
 
Follow-up 
Table 2 shows performance relating to follow-up. These results are based on a question that 
asked for specific follow-up intervals. The following number(s) of follow-up visits were recorded: no 
visits 179 (23%, range 5-51%); one visit 275 (35%, range 15-66%); two visits 80 (10%, range 0-
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20%); three visits 173 (22%, range 2-39%); four visits 21 (3%, range 0-8%); more than four visits 
29 (4%, range 0-12%), and other non-specified follow-up 24 (3%, range 0-8%). There were 127 
permutations of follow-up. Only 16 cases (2%) had follow-up at intervals approximating to 1, 2, 3, 
6 & 12 months (the minimum follow-up schedule recommended by the National Guidelines2).  
 
Table 3 shows the responses to an additional question about eventual follow-up outcomes. Only 
36% of cases were ascribed the ideal outcome of a seronegative or serofast non-treponemal test 
(NTT) titre and discharge at one year, mainly explained by three other responses, failing to return 
for follow-up (34%), lifetime annual follow (7%), and other reasons (16%). The following other 
reasons for not achieving this ideal outcome were as follows: follow-up at another centre  (34 
cases, 4%); negative NTT or serofast at less than 12 months (20 cases, 3%, of whom 3 cases 
were discharged); follow-up for HIV infection (15 cases, 2%); continuing management (14 cases, 
2%); other specified non-attendance (11 cases, 1.4%); annual follow-up for 5 years (6 cases, 
0.8%) – this outcome was reported from one Region only; moved away  (5 cases, 0.6%); negative 
NTT or serofast at 12 months but not discharged (2 cases, 0.3%, one case received an oral 
treatment, and the other parenteral treatment, both cases had negative tests for HIV infection), 
and various other responses for 19 (2%) cases. (See Discussion for further interpretation of this 
outcome). 
 
Based on final treatments (after treatment switches), 189 of 236 (80%) cases who received oral 
treatment and 414 of 513 (81%) cases who received parenteral treatment attended for follow-up. 
Only 56 cases were designated as requiring annual follow-ups. Of these, 17 (30%), including 9 
cases with HIV infection, had received oral treatment. Of the remaining 39 parenteral treatments, 
24 (62%) were cases with HIV infection. Hence, annual follow-up was only justified for 41 (73%) of 
these cases. Only 17 (7%) of all 236 oral treatments (including switches to oral treatment) were 
designated annual follow-up. Only 33 (27%) of 123 cases with HIV infection were recorded as 
having annual follow-up. Fifteen (4%) of 410 completed parenteral treatments for cases not known 
to have HIV infection were designated annual follow-up   
 
 
National Guideline outcomes 
Table 4 shows outcome performance compared against specific standards in the National 
Guidelines, 2 and against national average performances. A very wide range of resolution rates 
was recorded across the Regions. Nationally, 469 cases were designated as applicable for clinical 
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lesion resolution. Of these, 123 were oral treatments, 327 were parenteral treatments and one 
received both an oral and parenteral treatment, of whom 97(79%), 250 (76%) and none, 
respectively, were recorded as having lesion resolution. The remaining 18 cases comprised 8 
cases treated elsewhere, 6 for whom the question about resolution was not answered, 3 not 
treated and one case for whom resolution was not known.  
The low rate of recording a two dilution (fourfold) or greater decrease in NTT titre within 3-6 
months after treatment was explained by the following outcomes: failed to re-attend (152, 19%); 
expected titre drop not attained (117, 15%); not tested (26, 3%); other reasons (14, 2%); negative 
or neat titres at diagnosis (17, 2%), and this question was not answered for (36, 5%) cases. Of the 
117 cases not attaining an expected titre drop, 105 (90%) had a follow-up visit at 3 months and 48 
(41%) cases had a follow-up visit at 6 months. 
 
Recording of treatment completion also displayed a fairly wide performance range of about 30%. 
Nationally, of the 236 oral treatments (including switches to oral treatment and one case treated 
with both an oral and parenteral treatment), 195 (83%) were recorded as completed, and of the 
513 parenteral treatments, 494 (96%) were recorded as completed. Nationally, 90 (12%) 
treatments were not recorded as completed, accounted for by the following: no documentation of 
treatment completion for 42 (5%) cases, 13 (1.7%) cases were not treated based on this measure 
(note that 14 cases were not treated based on recorded treatments1), 11 (1.4%) cases were 
treated elsewhere and treatment completion could not be commented on, treatment not completed 
in 12 (1.5%) cases, and this question was not answered for 12 (1.5%) cases. 
 
Nationally, 511 adult traceable contacts were recorded as having being seen (at an own or other 
centre), and the range of performance, based on the National Guidelines standard of 60%2 for the 
proportion of traceable adults seen, was very wide at around 45%. However, 7 Regions achieved 
this standard or greater. Of the 98 cases not provided with contact tracing, 31 traceable contacts 
were recorded for 15 index cases, of whom 6 contacts were seen (contacts seen/traceable 
contacts = 19%). This contrasts with 966 traceable contacts (discounting one outlier with 60 
contacts) recorded for 683 index cases for whom contact tracing was provided and where 505 
contacts were seen (contacts seen/traceable contacts = 52%). 
The national ratio of number of traceable contacts seen to number of index cases was 0.66 
(regional range 0.29 to 0.97). 
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Discussion  
This Audit provides evidence that performance in contact tracing and follow-up of index cases with 
infectious syphilis in parts of the UK falls short of the recommendations in the National 
Guidelines.2 Both the National Guidelines contact tracing performance indicator and the adult 
positive contact rate were highly variable across the Regions. Achievement by 7 Regions of the 
National Guidelines contact tracing performance indicator supports the use of this standard. 
However, none of the aggregated performance rates for the London Regions achieved this 
standard (although 9 of the 23 participating London clinics did achieve this standard); the average 
performance for the London clinics against this standard was 44%. In their paper on contact 
tracing standards for gonorrhoea and genital chlamydial infection, Low and Radcliffe concluded 
that  “Standards set using expert opinion are unrealistic when compared to evidence of what is 
achievable. Evidence based methods should therefore be used to derive outcome standards…” 3 
Might this also be appropriate for infectious syphilis?  
 
Nationally, the proportion of adult contacts found to have syphilis was slightly below the rates 
found in previous studies referred to in the National Guidelines (42% vs 46% and 60%).4,5 
However, 8 Regions achieved rates within or above the range 46-60%. Good agreement between 
three questions used to measure contact tracing provision suggests that about 15% of cases were 
not provided with contact tracing. Very little is known about the clinic structures and processes in 
the UK that support good contact tracing outcomes. Also, improving contact tracing outcomes for 
infectious syphilis is an effectiveness issue in North America,6, 7, 8 although little has been 
published about this in the UK. 
 
The very low rates of recording of a two dilution (fourfold) or greater titre decrease in NTT titres 
within 3-6 months after treatment was mainly attributable to patients not attending for follow-up 
and failure of titre levels to fall. As NTT titres may take longer to decline in early latent syphilis 
compared to primary and secondary syphilis, use of this interval may not be appropriate for early 
latent syphilis.9 However, exclusion of early latent cases increased overall performance against 
this standard by only 5% to 59%. The other NTT titre outcome audited was a seronegative or 
serofast NTT titre and discharge after one year of follow-up. Table 3 shows performance recorded 
against this standard for all cases. However, performance against this outcome was really only 
applicable to 427 cases who had parenteral treatment and who were not known to have HIV 
infection: based on this denominator, 164 (38%) of these cases met this standard, only a small 
increase in performance (this denominator also excludes 27 cases who were not treated, were 
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treated elsewhere or where data about treatment was not provided). On the other hand, 327 (42%) 
cases received an oral treatment and/or had HIV infection, and would not therefore have been 
eligible for discharge after one year. However, meeting this standard was reported for 111 (34%) 
of these cases, even though the criteria for discharge were not met.  
 
Based on a range of measures, there appear to be highly variable follow-up rates between 
Regions. Approximately three quarters of index cases attended for follow-up, but only half this 
number attended for at least two visits. In contrast to the management of gonorrhoea and genital 
chlamydia, where reducing the number of return visits to clinics may be appropriate, follow-up for 
serological tests is an essential aspect of management for infectious syphilis. Additionally, this 
Audit suggests that annual follow-up is not usually provided to cases receiving oral treatment. It is 
likely that most cases with HIV infection will have continued with follow-up, although this seems to 
have been poorly documented. 
 
 
 
Conclusions and suggested areas for practice improvement/intervention 
Further study is needed of UK genitourinary medicine clinic service structures and processes, as 
well as patient factors, in order to determine factors accounting for wide ranges in contact tracing 
and follow-up performance. Any possible impact of the current problems in meeting patient 
demand for services in UK genitourinary medicine clinics10 on contact tracing and follow-up for 
cases of infectious syphilis requires urgent attention. 
 
All patients with infectious syphilis should be provided with contact tracing. It is possible that 
immediate (e.g. dark ground microscopy) or other interventions to achieve early diagnosis may 
help to facilitate this. Finally, exploration of contact tracing methods to improve outcomes may be 
warranted in the UK.  
  
 
 
Detailed data, aggregated by Region, are available on the BASHH website: 
http://www.bashh.org/committees/nag/index.htm 
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 Table 1   Contact tracing performance in early syphilis (N=781 unless otherwise stated) 
Contact tracing indicator Number (National average as %) Regional ranges as % 
Contact tracing provision 683 (87) 57-97 
Contact tracing provider*   
Health Adviser  611 (78) 57-97 
Doctor 111 (14) 0-35 
Nurse  42 (5) 0-16 
Other 2 (0.3) 0-3 
Not answered:  108 (14) 3-43 
Any healthcare provider 673 (86) 57-97 
Positive adult contacts/contacts seen (n= 511)† 215 (42) 3-73 
Children seen/traceable children (n=13) 12 (92) 0-100 
Positive cases in children (n=13) 0 (0) Not applicable 
*More than one choice of provider was used 
†One outlier index with 60 contacts discounted 
 
 
 
 
 
 
 
 
 
 
Table 2   Follow-up of cases with early syphilis (N=781) 
Follow-up indicator Number (National average as %) Regional ranges as % 
Any follow-up 604 (77) 49-95 
At least two follow-up visits 
 
312 (40) 5-61 
Follow-up during selected intervals   
Up to 6 weeks 230 (29) 9-57 
7 weeks to 4 months 328 (42) 10-67 
> 4 months to 9 months 175 (22) 6-44 
> 9 months to 12 months 182 (23) 0-37 
> 12 months 32 (4) 0-12 
1, 2, 3 months 136 (17) 2-28 
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Table 3   Follow-up outcomes in early syphilis (N=781) 
Follow-up outcome* Number (National average as %) Regional ranges as % 
VDRL/RPR negative/serofast at 1year after 
treatment, patient discharged†  
276 (36) 13-56 
Re-infected/retreated 
 
23 (3) 0-6 
Clinical relapse, retreated 3 (0.4) 0-4 
Failed to return 262 (34) 16-55 
Treatment failed, retreated 10 (1) 0-4 
Annual follow-ups for life 56 (7) 0-20 
Negative initial tests repeated at 3 months 15 (2) 0-4 
Other 126 (16) 0-57 
Not answered 15 (2) 0-10 
*More than one choice of follow-up outcome was used 
† Denominator excludes 15 cases with negative initial tests repeated at 3 months 
 
 
 
 
Table 4   Performance against outcome measures listed by Clinical Effectiveness Group for early 
syphilis management (N=781 unless otherwise stated) 
Outcome measure Standard 
Number (National 
average as %) 
Regional ranges as 
% 
Resolution of clinical lesions Not specified   
All stages* (n=469†)  348 (74) 40-96 
Primary syphilis (n =231†)  176 (76) 33-100 
Secondary syphilis (n =193†)  149 (77) 12-100 
Two dilution (fourfold) or greater decrease in VDRL/RPR 
titre within 3-6 months after treatment (n=764‡) 
Not specified 419 (55) 37-70 
Completion of treatment 95% 691 (88) 71-100 
Adult contacts seen/traceable adult contacts (n=997)§ 60% 511 (51) 26-70 
*Included 43 cases of early latent syphilis, one re-infection and one case not classified 
†Cases recorded as not applicable for resolution are excluded from these figures 
‡17 cases with negative or neat titres at diagnosis excluded 
§One outlier index with 60 contacts discounted 
 
 
END. 
